Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
Phase 2 Terminated
1 enrolled
AMEERA-3
Phase 2 Terminated
367 enrolled 30 charts
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Phase 2 Terminated
21 enrolled 15 charts
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Phase 2 Terminated
7 enrolled 10 charts
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Phase 2 Terminated
6 enrolled
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Terminated
4 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Phase 2 Terminated
64 enrolled 21 charts
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Phase 1 Terminated
33 enrolled
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Phase 1 Terminated
6 enrolled
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Phase 2 Terminated
4 enrolled 7 charts
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Phase 1/2 Terminated
46 enrolled
IPATunity150
Phase 1 Terminated
20 enrolled 11 charts
EPIK-B4
Phase 2 Terminated
2 enrolled 8 charts
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
Phase 1 Terminated
124 enrolled 23 charts
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Phase 1 Terminated
674 enrolled 55 charts
TELEPIK
Phase 2 Terminated
2 enrolled 10 charts
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Phase 2 Terminated
11 enrolled 10 charts
SUMMIT
Phase 2 Terminated
582 enrolled 27 charts
PASIPHAE
Phase 2 Terminated
42 enrolled
VERU-024
Phase 3 Terminated
5 enrolled
DEMETER
Phase 2 Terminated
1 enrolled
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
Phase 2 Terminated
1 enrolled 5 charts
MK-4440-001
Phase 1 Terminated
78 enrolled 28 charts
SAFIR-PI3K
Phase 2 Terminated
31 enrolled
SANDPIPER
Phase 3 Terminated
631 enrolled 49 charts
Veronica
Phase 2 Terminated
103 enrolled 19 charts
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Phase 2 Terminated
2 enrolled 7 charts
Phase II Study of Everolimus Beyond Progression
Phase 2 Terminated
3 enrolled 4 charts
PRECYCLE
Phase 4 Terminated
532 enrolled
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Phase 4 Terminated
4 enrolled 9 charts
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
Phase 1 Terminated
2 enrolled 5 charts
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
107 enrolled
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Phase 2 Terminated
2 enrolled 5 charts
SHERBOC
Phase 2 Terminated
22 enrolled 16 charts
BELLE-3
Phase 3 Terminated
432 enrolled 20 charts
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Phase 2 Terminated
97 enrolled 18 charts
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
Phase 2 Terminated
12 enrolled 7 charts
Neohttp
Phase 1/2 Terminated
4 enrolled 1 chart
ZACFAST
Phase 2 Terminated
39 enrolled 7 charts
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Phase 2 Terminated
97 enrolled 10 charts
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Phase 1/2 Terminated
11 enrolled 6 charts
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
Phase 2 Terminated
4 enrolled 8 charts
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Phase 2 Terminated
15 enrolled
Study of AFP464 +/- Faslodex in ER + Breast Cancer
Phase 2 Terminated
7 enrolled
Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Phase 2 Terminated
18 enrolled